EP Patent

EP4374853A1 — Solid formulation of enzalutamide

Assigned to Lotus Pharmaceutical Co Ltd · Expires 2024-05-29 · 2y expired

What this patent protects

The present invention provides a solid pharmaceutical composition comprising a premix containing enzalutamide and hydroxypropylmethyl cellulose phthalate (HPMC-P). The composition may further contain at least one filler, at least one disintegrant, at least one glidant and/or at l…

USPTO Abstract

The present invention provides a solid pharmaceutical composition comprising a premix containing enzalutamide and hydroxypropylmethyl cellulose phthalate (HPMC-P). The composition may further contain at least one filler, at least one disintegrant, at least one glidant and/or at least one lubricant. The composition has similar dissolution properties to the reference product, while simultaneously showing a very good bioavailability.

Drugs covered by this patent

Patent Metadata

Patent number
EP4374853A1
Jurisdiction
EP
Classification
—
Expires
2024-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Lotus Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.